Novo Holdings A/S invests in US healthcare IT company Availity
Strategic health IT investment will strengthen payer-provider collaboration and reduce waste in … Continue reading “Novo Holdings A/S invests in US healthcare IT company Availity”
Strategic health IT investment will strengthen payer-provider collaboration and reduce waste in … Continue reading “Novo Holdings A/S invests in US healthcare IT company Availity”
STIMULAN® when mixed with antibiotics is the only calcium matrix approved for … Continue reading “Biocomposites announces new approval for STIMULAN® to treat bacterial infection”
Experienced Industry Leader with successful Oncology, Immunotherapy & ADC Development Track Record … Continue reading “Adcendo Appoints Michael Pehl as Chief Executive Officer”
GDT-002 is a potential first-in-class cellular immunotherapy UTRECHT, Netherlands and BOSTON, July 6, 2021 /PRNewswire/ — Gadeta … Continue reading “First Patient Dosed with Gadeta’s gamma delta TCR Cell Therapy”
Brighton, United Kingdom – 02 July 2021 – Destiny Pharma plc (AIM: DEST), a clinical … Continue reading “Destiny Pharma Scientific Advisor, Professor Dale Gerding, to chair C. diff. Foundation Symposium”
Bionical Solutions, a leading provider of technology enabled engagement and healthcare services … Continue reading “Bionical Solutions Appoints David Bournes As Business Development Director”
Salvia BioElectronics B.V. (“Salvia”), a neurostimulation platform company targeting chronic migraine, announces … Continue reading “Salvia BioElectronics appoints Dr Alan Levy as Chairman”
Optimum is pleased to announce the appointment of Stella Lempidaki. With a … Continue reading “Optimum Strategic Communications Expands Team to support ongoing growth”
Brighton, United Kingdom – 29 June 2021 – Destiny Pharma plc (AIM: DEST), … Continue reading “Destiny Pharma to present at the Shares and AJ Bell Investor Webinar on 06 July 2021”
The objective is to make RNA therapeutics accessible to global patient populations. … Continue reading “eTheRNA immunotherapies and Quantoom Biosciences Announce a Strategic Collaboration for the Development of a Novel RNA Production System”
Extension to proven TriMix® adjuvant technology intended to boost dendritic cell activation Niel … Continue reading “eTheRNA and VUB expand strategic collaboration to engineer next generation mRNA therapeutics with TetraMix®”
• Artios’ small molecule Polθ inhibitor elicits BRCA-gene synthetic lethality and PARP … Continue reading “Artios Pharma Publishes Preclinical Data on The First Selective Small Molecule Polθ Polymerase Inhibitor in Nature Communications”
Novo Holdings A/S, a leading global life sciences investor, today announced it … Continue reading “Novo Holdings acquires BBI Group”
COPENHAGEN, Denmark, June 11, 2021 – Bavarian Nordic A/S (OMX: BAVA) announced today … Continue reading “Bavarian Nordic Assists Public Health England In Response To New Cases Of Monkeypox”
$40 million upfront including $25 million cash and $15 million in equity … Continue reading “Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China”
XF-73 met its primary end point with >99% nasal aureus reduction within 24 hours … Continue reading “Destiny Pharma: XF-73 data abstract to be presented at 2021 ECCMID”
vasopharm GmbH, a privately-held biopharmaceutical company focusing on novel therapeutics for the … Continue reading “vasopharm Announces Results of the Nostra III Traumatic Brain Injury Phase III Study”
Company co-created and funded by Novo Holdings and HealthCap Breakthrough asset in-licensed … Continue reading “Novo Seeds Launches Tribune Therapeutics to Develop Novel Medicines Targeting a Wide Range of Fibrotic Diseases”
Positive update on microbiome therapeutic NTCD-M3 for recurrent C. difficile infections · Preparations for … Continue reading “Destiny Pharma: Positive update on microbiome therapeutic NTCD-M3 for recurrent C. difficile infections”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2021 Optimum Strategic Communications All rights reserved.
8 Devonshire Square
Spitalfields
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com
